Sunshine Biopharma Inc. Loan Processing Fee
Sunshine Biopharma Inc. (SBFM) reported Loan Processing Fee of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LoanProcessingFee · last filed 2021-03-30
- Sunshine Biopharma Inc. loan processing fee for the quarter ending 2020-12-31 was -$7.00K, a 220.69% decline year-over-year.
- Sunshine Biopharma Inc. loan processing fee for the quarter ending 2020-09-30 was $3.00K, a 53.85% decline year-over-year.
- Sunshine Biopharma Inc. loan processing fee for the quarter ending 2020-06-30 was $4.00K.
- Sunshine Biopharma Inc. loan processing fee for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Sunshine Biopharma Inc. loan processing fee for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Sunshine Biopharma Inc. loan processing fee for fiscal 2019 was $28.23K, a 50.56% increase from fiscal 2018.
- Sunshine Biopharma Inc. loan processing fee for fiscal 2018 was $18.75K, a 25.00% decline from fiscal 2017.
- Sunshine Biopharma Inc. loan processing fee for fiscal 2017 was $25.00K, a 12.05% increase from fiscal 2016.
| Period end | Loan Processing Fee 3 month | Loan Processing Fee 6 month | Loan Processing Fee 9 month | Loan Processing Fee 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | -$4.00K derived: sum of 2 quarters · filed 2021-03-30 | $0.00 derived: sum of 3 quarters · filed 2021-03-30 | $0.00 10-K · filed 2021-03-30 |
| 2020-09-30 | $3.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-12 | $7.00K derived: sum of 2 quarters · filed 2020-11-12 | $7.00K 10-Q · filed 2020-11-12 | $12.80K derived: sum of 4 quarters · filed 2021-03-30 |
| 2020-06-30 | $4.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-31 | $4.00K 10-Q/A · filed 2020-08-31 | $9.80K derived: sum of 3 quarters · filed 2021-03-30 | $16.30K derived: sum of 4 quarters · filed 2021-03-30 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-18 | $5.80K derived: sum of 2 quarters · filed 2021-03-30 | $12.30K derived: sum of 3 quarters · filed 2021-03-30 | $12.30K derived: sum of 4 quarters · filed 2021-03-30 |
| 2019-12-31 | $5.80K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $12.30K derived: sum of 2 quarters · filed 2021-03-30 | $12.30K derived: sum of 3 quarters · filed 2021-03-30 | $28.23K 10-K · filed 2021-03-30 |
| 2019-09-30 | $6.50K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-12 | $6.50K derived: sum of 2 quarters · filed 2020-11-12 | $22.43K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-31 | $15.93K 10-Q/A · filed 2020-08-31 | ||
| 2019-03-31 | $15.93K 10-Q · filed 2020-05-18 | |||
| 2018-12-31 | $18.75K 10-K · filed 2020-05-01 | |||
| 2017-12-31 | $25.00K 10-K · filed 2019-04-12 | |||
| 2016-12-31 | $22.31K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |